Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Finally, we used our approach to assess binding of Vitamin D binding protein (GC) to Vitamin D (Supplementary Fig. 2), Fructose-bisphosphate aldolase A (ALDOA) to fructose bisphosphate (Supplementary Fig. 3), and Thyroxine Binding Globulin (TBG) to thyroxine (Supplementary Fig. 4), in all cases re-analysing data from a previous study in which we added the compounds to purified proteins and comparing proteolytic patterns in the presence versus absence of the compound34.

Source: An amino acid-resolution analytical approach for high-coverage LiP-MS data. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

Study design awaiting verification · NPJ Parkinson's Disease · 2025

Original publication title

An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

P. Stalder; T. Serdiuk; D. Ghosh; Y. Fleischmann; N. Ait-Bouziad; J.-P. Quast; L. Malinovska; A. Ouared; A. Davranche; W. Haenseler; C. Boudou; E. Tsika; J. Stöhr; R. Melki; R. Riek; N. de Souza; P. Picotti

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Amyloid aggregation is associated with neurodegenerative disease and its modulation is a focus of drug development. We developed a chemical proteomics pipeline to probe the mechanism of action of anti-amyloidogenic compounds. Our approach identifies putative interaction sites with high resolution, can probe compound interactions with specific target conformations and directly in cell and brain extracts, and identifies off-targets. We analysed interactions of six anti-amyloidogenic compounds and the amyloid binder Thioflavin T with different conformations of the Parkinson’s disease protein α-Synuclein and tested specific compounds in cell or brain lysates.

AC Immune compound 2 interacted with α-Synuclein in vitro, in intact neurons and in neuronal lysates, reduced neuronal α-Synuclein levels in a seeded model, and had protective effects. EGCG, Baicalein, ThT and doxycycline interacted with α-Synuclein in vitro but not substantially in cell lysates, with many additional putative targets, underscoring the importance of testing compounds in situ. Our pipeline will enable screening of compounds against any amyloidogenic proteins in cell and patient brain extracts and mechanistic studies of compound action.

Authors’ abstract

Amyloid aggregation is associated with neurodegenerative disease and its modulation is a focus of drug development. We developed a chemical proteomics pipeline to probe the mechanism of action of anti-amyloidogenic compounds. Our approach identifies putative interaction sites with high resolution, can probe compound interactions with specific target conformations and directly in cell and brain extracts, and identifies off-targets. We analysed interactions of six anti-amyloidogenic compounds and the amyloid binder Thioflavin T with different conformations of the Parkinson’s disease protein α-Synuclein and tested specific compounds in cell or brain lysates.

AC Immune compound 2 interacted with α-Synuclein in vitro, in intact neurons and in neuronal lysates, reduced neuronal α-Synuclein levels in a seeded model, and had protective effects. EGCG, Baicalein, ThT and doxycycline interacted with α-Synuclein in vitro but not substantially in cell lysates, with many additional putative targets, underscoring the importance of testing compounds in situ. Our pipeline will enable screening of compounds against any amyloidogenic proteins in cell and patient brain extracts and mechanistic studies of compound action.

Publication and source details

Original title: An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

P. Stalder; T. Serdiuk; D. Ghosh; Y. Fleischmann; N. Ait-Bouziad; J.-P. Quast; L. Malinovska; A. Ouared; A. Davranche; W. Haenseler; C. Boudou; E. Tsika; J. Stöhr; R. Melki; R. Riek; N. de Souza; P. Picotti

NPJ Parkinson's Disease · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Personalized Health and Related Technologies grant (PHRT-506) Synapsis Foundation: Alzheimer Research Switzerland ARS Swiss National Science Foundation (SNSF grant CRSII5_177195) Peter Bockhoff Stiftung ETH Zurich foundation Parkinson Schweiz EMPIRIS Foundation grant (2022-FS-353) The European Research Council (866004) The EPIC-XS Consortium (823839)

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:15:02.773105+00:00

DOI: 10.1038/s41531-025-00966-5 · PMC12065871